Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia

L. Karawajew, M. Dworzak, R. Ratei, P. Rhein, G. Gaipa, B. Buldini, G. Basso, O. Hrusak, WD. Ludwig, G. Henze, K. Seeger, A. von Stackelberg, E. Mejstrikova, C. Eckert,

. 2015 ; 100 (7) : 935-944. [pub] 20150522

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010163

Grantová podpora
NT13462 MZ0 CEP - Centrální evidence projektů

Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002 clinical trial information: NCT00114348.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010163
003      
CZ-PrNML
005      
20191010112956.0
007      
ta
008      
160408s2015 it f 000 0|engg|
009      
AR
024    7_
$a 10.3324/haematol.2014.116707 $2 doi
024    7_
$a 10.3324/haematol.2014.116707 $2 doi
035    __
$a (PubMed)26001791
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Karawajew, Leonid $u Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany leonid.karawajew@charite.de.
245    10
$a Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia / $c L. Karawajew, M. Dworzak, R. Ratei, P. Rhein, G. Gaipa, B. Buldini, G. Basso, O. Hrusak, WD. Ludwig, G. Henze, K. Seeger, A. von Stackelberg, E. Mejstrikova, C. Eckert,
520    9_
$a Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002 clinical trial information: NCT00114348.
650    _2
$a CD antigeny $x genetika $x imunologie $7 D015703
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a B-lymfocyty $x účinky léků $x imunologie $x patologie $7 D001402
650    _2
$a nádorové biomarkery $x genetika $x imunologie $7 D014408
650    _2
$a kostní dřeň $x účinky léků $x imunologie $x patologie $7 D001853
650    _2
$a předškolní dítě $7 D002675
650    _2
$a DNA-nukleotidylexotransferasa $x genetika $x imunologie $7 D004253
650    _2
$a průtoková cytometrie $x metody $7 D005434
650    _2
$a exprese genu $7 D015870
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a kojenec $7 D007223
650    _2
$a reziduální nádor $7 D018365
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a pre-B-buněčná leukemie $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D015452
650    _2
$a protoonkogenní proteiny c-bcl-2 $x genetika $x imunologie $7 D019253
650    _2
$a recidiva $7 D012008
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dworzak, Michael $u St. Anna Children's Hospital and Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria.
700    1_
$a Ratei, Richard $u Robert-Roessle-Clinic in the HELIOS Klinikum Berlin, Germany.
700    1_
$a Rhein, Peter $u Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany.
700    1_
$a Gaipa, Giuseppe $u Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca, Ospedale San Gerardo, Monza, Italy.
700    1_
$a Buldini, Barbara $u Laboratory of Pediatric Onco-Hematology, Department of Pediatrics, University Hospital of Padova, Italy.
700    1_
$a Basso, Giuseppe $u Laboratory of Pediatric Onco-Hematology, Department of Pediatrics, University Hospital of Padova, Italy.
700    1_
$a Hrušák, Ondřej, $u Department of Pediatric Hematology and Oncology, Charles University 2 Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. $d 1965- $7 xx0036691
700    1_
$a Ludwig, Wolf-Dieter $u Robert-Roessle-Clinic in the HELIOS Klinikum Berlin, Germany.
700    1_
$a Henze, Günter $u Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany.
700    1_
$a Seeger, Karl $u Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany.
700    1_
$a von Stackelberg, Arend $u Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany.
700    1_
$a Mejstříková, Ester, $u Department of Pediatric Hematology and Oncology, Charles University 2 Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. $d 1977- $7 xx0105223
700    1_
$a Eckert, Cornelia $u Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 100, č. 7 (2015), s. 935-944
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26001791 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20191010113415 $b ABA008
999    __
$a ok $b bmc $g 1113592 $s 934531
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 100 $c 7 $d 935-944 $e 20150522 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a NT13462 $p MZ0
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace